Memphis Meats' lab-produced meatballs
There is a frustrating, 'jam tomorrow' aspect to all the talk around cell-based meat.
Perhaps it is the tantalising prospect of what might be achieved by the men and women in labs and what it might mean for the future of food that makes us keep asking the question of when we will see something more than a prototype of meat created without harming animals.
But the answer always seem to be that we are a couple of years away.
However, there do seem to be signs of progress. Specifically, costs associated with the process, previously sky high, do seem to be coming down.
It should be remembered that it was back in 2013 when Mosa Meat of the Netherlands created the world's first lab-grown burger at the eye-watering cost of EUR250,000 (US$295,594 at today's conversion rate).
Here we are seven years later and the products are still in the lab, seemingly a long way from supermarket shelves.
On the face of it, even for a layman, what is being done in those labs is relatively easy to understand.
Stem cells are taken from the muscle of an animal and added to a nutrient rich-solution called cell culture medium typically containing vitamins, sugars and proteins and left to multiply, or fatten, to create meat.
The environmental and animal-welfare benefits of this process succeeding has meant the nascent industry has enjoyed more media attention and investment dollars than many other areas of food product development, with the exception of plant-based meat alternatives, also known as alt-protein.
But, as was demonstrated seven years ago, the central issue facing the industry is no longer proof of concept. It can be done, even with trickier marbled cuts of meat such as steak, but can it be done at scale and at an affordable cost?
Some investors think so as they continue to back cell-based meat companies, enticed by the prospect of getting in early to a development offering so much promise on paper (and lab desk).
In January, Memphis Meats of the US secured US$161m in new funding with meat giant Tyson Foods once again among the consortium of investors.
The California-based company said in January it will use the funds to build a pilot production plant, expand its team and to "hit a major milestone of launching products into the market". However, it has not set an actual launch date.
David Kay, Memphis Meats' senior manager of communications and operations, tells just-food the company needs to develop additional infrastructure for production, with a pilot production facility a key element.
"The focus is on reducing the cost of production and increasing production scale. On both of these issues, we have made very significant progress since we were founded in 2015," Kay insists.
Mosa Meat is still pushing hard to get a product ready to scale up. It too has attracted investment from established food companies. Last month, Switzerland's Bell Food Group agreed to put EUR5m in the Dutch business.
Beckie Calder-Flynn, Mosa Meat's operations co-ordinator, says: "We are aiming for a first market introduction in the next few years. It is very difficult to commit to a particular time frame because there are still some scientific unknowns and factors outside our control, such as the regulatory process.
"The first introduction will likely be small-scale. Several years beyond that, we aim to be widely available in supermarkets and restaurants."
The thorny issue of the cost of producing at scale is never far from the surface.
Calder-Flynn says: "As with any technology, initial prices tend to be extremely high until the product is commercialised, production is made efficient, and then products are sold en masse.
"For us, we are currently working on up-scaling our equipment so that we can produce large quantities quickly and efficiently. This hasn't been done before and is complex.
"We estimate that commercialisation will bring the price of a burger down to EUR9.00, compared with the EUR250,000 it cost to make the first burger. The cost of a hamburger in the supermarket is around EUR1.00 and we expect that with further efficiency improvements we will be able to bring the price down to this level over the next decade.
"Ultimately, cultured meat should be cheaper than conventional meat given its production is more efficient. One cell sample can create up to 10,000kg of cultured meat. Our estimates suggest that at that rate we would only need 150 cows to satisfy the world's current meat demand.
"The bottleneck currently is production efficiency and speed. It takes about ten weeks to make a [cell-based] hamburger, which is obviously not suitable for commercial production, but this doesn't mean we can't produce at industrial scale in the future. Because cell growth is exponential, it takes ten weeks to produce one quarter pound hamburger, but only about 12 weeks to produce 100,000 hamburgers."
Mosa Meat claimed another breakthrough on cost recently when the company announced it had achieved an 80x reduction in the cost of the growth medium or nutrient mix for its lab-grown meat.
Part of that transition is to move away from FBS (Fetal Bovine Serum), the standard growth medium used by the cell-based meat industry.
California-based New Age Meats is another business at the forefront of the cell-based charge. At the end of July, it secured $2m from investors just six months after raising $2.7m in seed funding from a consortium of backers.
The company said the new seed extension funding will help it to continue to develop cell-based pork products.
Specifically, New Age Meats plans to further expand its food science department, implement more automation and robotics and continue to attempt to reduce the cost of its first lab-produced product, a pork sausage.
Like its rivals, New Age Meats is now working towards building a pilot facility, scaling product development and production and getting its first foods to market.
Derin Alemli, director of operations and finance at the business, admitted development has slowed down because of the coronavirus pandemic.
"Covid has set the process back a little bit. We've been figuring out how to get back into the lab. We are at about 80% capacity now so we are making progress," he says.
Alemli believes the company's focus on pork gives it a distinct advantage. "Pigs are highly researched animals and there's a huge market for it. Our first product is a pork sausage because it's easier to use pork than a marbled product such as steak."
On the issue of cost, Alemli is optimistic about the future of lab-created products.
"The costs have come down dramatically to the $800-$1,000 a pound range," he says. "The equipment is expensive but that is a one-off cost. It's the media to feed the cells [that ratchets up costs]. "If we are not at the $15-$20 a pound range in the future that's tough sledding."
Also working hard to create lab-based meat is the French company Gourmey. The company is attempting to create a cruelty-free version of foie gras.
The French delicacy, which directly translates as "fat liver," is traditionally made out of the liver of a duck or goose which has been force-fed or over-fed.
Company co-founder and CEO Nicolas Morin-Forest tells just-food Gourmey is building a "versatile platform" around duck stem cells.
"With our cells' ability to specialise into any cell type, including muscle cells, we will also bring more complex cuts of meat at some point once the scaffold-based cultured meat technologies will have matured," he says.
Morin-Forest will not commit to a specific launch date at this stage.
"We are currently working on a lab-scale foie gras prototype and will showcase it in the next months," he says.
Jack Bobo, the CEO of Futurity, a Washington DC-based "food foresight company that helps brands get ahead of trends," is someone who has kept a close eye on developments in the cell-based area.
In terms of timescale for scaling up production, he says: "Some of the companies have got a very aggressive timeline. Others say they are some way off from commercialisation. Certainly there is some hype around businesses trying to get exposure to the media and investors. Companies with adequate funding are a lot less aggressive in what they are saying."
Bobo, a former special adviser on food policy at the US Department of State, suggests there are "some real technical issues that companies are still tackling".
He also thinks they can be communicating their message better. "I have talked privately to some of these companies and I told them to drop the term 'clean meat'. If I was running a company I would not want to be sitting down with a journalist and talking about safety and ethics.
"It's highly offensive to livestock producers and ended up with 28 states trying to stop them using the term meat. It was a self-inflicted wound. If you are getting close to market you need to communicate to the market better."
Of course, getting that product to market depends on regulatory approval and success ultimately depends retailers and consumers wanting to eat cell-based meat.
On the regulatory front, the US seems further ahead than Europe.
In March 2019, the Department of Agriculture (USDA) and the Food and Drug Administration (FDA) announced they'd established a framework for regulating cell-based meat and poultry.
The USDA will oversee food processing, labelling and distribution and the FDA will conduct inspections and safety checks. Within the European Union, food produced from cell culture or tissue culture derived from animals falls within the scope of the EU Novel Foods Regulation. There are those in cell-based meat space that see the US as having made more progress on the regulation of the fledgling sectorthan the EU, with some entrepreneurs wanting more engagement from Brussels and asking whether its process needs to take the time it does. The EU's Novel Foods Regulation takes up to two years in practice to go through.
Getting retailers and consumers on board is, of course, then also key once any approval is handed down.
Kay at Memphis Meats is confident in this regard. He says: "Research suggests that roughly two-thirds of Americans would eat cell-based meat, and that the more consumers learn about our products, the more enthusiastic they become.
"We are anticipating a lot of excitement from consumers, and we've already heard from many major retailers and restaurant chains that are interested in our work."
Calder-Flynn at Mosa Meat agrees. "We receive emails every day from people all around the world who are excited and passionate about cultured meat and the vast majority of responses we get about our work are extremely positive. People are wanting to eat healthier, more sustainable, and animal-friendly meat and they strongly believe cultured meat can offer that."
Alemli at New Age Meats says the research it has seen and done shows there will be early adopters if it is at the right cost. "The rise in alt-protein is good for us."
He suggest ethics and a post-Covid focus on safety will also come into play. "The inside of a slaughterhouse is not an appetising place. Our environment is very sanitary. It is safer, better for the environment."
When considering when such products will see the light of day, could the answer be in hybrid products, linking animal cells and plant-based ingredients?
Alemli at New Age Meats says his company's sausage is "more of a hybrid product", adding: "I think hybrid is a way of getting consumers ready for it and getting to market at a quite reasonable cost."
A company developing hybrid products is none other than KFC, the global fast-food chicken giant.
In July, KFC announced it had joined forces with Russian firm 3D Bioprinting Solutions, which is developing additive bioprinting technology that uses a recipe of chicken cells and plant ingredients. The resulting product is likely to be trialled in Russia.
What the move demonstrates is even mainstream majors are starting to think about the concept of cell-based meat and how it can benefit their businesses.
And while they can be accused of many things, being slow to market isn't one of them.
Read the original:
A question of scale the growing pains of cell-based meat - just-food.com
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
- Is Phenq Right For You? Review The Facts Before Making a ... - Vashon-Maury Island Beachcomber - November 27th, 2023
- Cavityn Reviews - Does It Work? Cheap Scam or Effective ... - The Daily World - November 25th, 2023
- Trend Hunting With Beautystreams At Cosmoprof Asia 2023 - BeautyMatter - November 25th, 2023
- FDA Considers First CRISPR Gene Editing Treatment That May ... - Slashdot - November 25th, 2023
- How Do Plants Determine Where the Light Is Coming From? - Lab Manager Magazine - November 25th, 2023
- Deaths From Coal Pollution Have Dropped, But Emissions May be ... - Slashdot - November 25th, 2023
- Stem cell-based therapies for stroke in newborns - Cochrane - November 23rd, 2023
- Dr Leslie on Outpatient CAR T-Cell Therapy Programs for ... - OncLive - November 23rd, 2023
- Human Milk-Based Therapy May Be Beneficial in Blood Cancers - Curetoday.com - November 23rd, 2023
- Oncological Horizons: The Synergy of Medical and Surgical ... - Cureus - November 23rd, 2023
- Human and environmental safety of carbon nanotubes across their ... - Nature.com - November 23rd, 2023
- Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted ... - BioSpace - November 23rd, 2023
- #HearTheMarsdenKids call on NHS London to reconsider cancer ... - Metro.co.uk - November 23rd, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with ... - Dove Medical Press - November 23rd, 2023
- BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire - November 21st, 2023
- Why our Award Winners Beauty Box is the ultimate beauty gift (for ... - Yahoo Singapore News - November 21st, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or ... - Vashon-Maury Island Beachcomber - November 21st, 2023
- Legend Biotech Reports Third Quarter 2023 Results and Recent ... - StreetInsider.com - November 21st, 2023
- Lorenzo's Oil: Can It Really Treat ALD? - Verywell Health - November 19th, 2023
- Doctor Says Living To 120 By End Of Decade Is Possible What's the Secret? - Benzinga - November 19th, 2023
- The week in pharma: action, reaction and insight week to ... - The Pharma Letter - November 19th, 2023
- Race Cannot Be Used To Predict Heart Disease, Scientists Say ... - Slashdot - November 19th, 2023
- SpaceX's Starship Reaches Outer Space Before Intentional ... - Slashdot - November 19th, 2023
- Mesenchymal Stem Cells Market is projected to reach USD 3,319 million by 2030 according to a new research r... - WhaTech Technology and Markets News - November 17th, 2023
- LMRUK: Protecting the next generation through cord blood - Charity Today News - November 17th, 2023
- Anti-aging molecule discovered that extends lifespan - Earth.com - November 17th, 2023
- Montana State researcher envisions living building materials that ... - Montana State University - November 17th, 2023
- OxyHelp Explores the Benefits of Hyperbaric Oxygen Therapy for ... - StreetInsider.com - November 15th, 2023
- Health benefits of bone marrow - Pakistan Observer - November 15th, 2023
- Evolving the standard of care: What is next for functional ... - NeuroNews International - November 15th, 2023
- Affimed Reports Third Quarter 2023 Financial Results and ... - BioSpace - November 15th, 2023
- Meet the World's First Whole-Eye Transplant Recipient - TIME - November 15th, 2023
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and ... - Business Wire - November 15th, 2023
- 10 Asia-Pacific biotech companies leading innovation in the region - Labiotech.eu - November 15th, 2023
- Fitspresso Reviews (November Update) Natural Ingredients That ... - Bainbridge Island Review - November 15th, 2023
- 2seventy bio Reports Third Quarter Financial Results and Recent ... - Business Wire - November 15th, 2023
- Japan To Create $6.6 Billion Fund To Develop Outer Space Industry ... - Slashdot - November 15th, 2023
- Be The Match, Healthcare Marketing Impact Awards 2023 - Ad Age - November 13th, 2023
- Medicare coverage saves lives. Enrolling shouldn't be this ... - Kevin MD - November 13th, 2023
- Future Ocean Foods: 36 Global Alt-Seafood Startups Form Association To Tackle Overfishing, Microplastics & More - Green Queen Media - November 13th, 2023
- Orchard Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 13th, 2023
- Celebrity doctor reveals Hollywoods hidden trend of stem cell antiaging therapies - Longevity.Technology - November 11th, 2023
- Amazon Expands Healthcare Push With One Medical Benefits For ... - Slashdot - November 11th, 2023
- Bene Meat Technologies becomes the first to receive EU approval ... - Pet Food Processing - November 11th, 2023
- FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma - Yahoo Finance - November 11th, 2023
- MaaT Pharma Provides Third Quarter 2023 Business Update and ... - Business Wire - November 11th, 2023
- IN8bio Reports Third Quarter 2023 Financial Results and Provides ... - GlobeNewswire - November 11th, 2023
- Fast Lean Pro Reviews - Overpriced or Optimal Ingredients That ... - Journal of the San Juan Islands - November 11th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - GlobeNewswire - November 11th, 2023
- Worlds first whole-eye and partial face transplant gives Arkansas man new hope - CNN - November 9th, 2023
- Glowing Fingertips And Green Eyes: First-of-Its-Kind Monkey ... - ScienceAlert - November 9th, 2023
- 10 Natural Body Scrubs That Exfoliate And Invigorate My Skin - PINKVILLA - November 9th, 2023
- CRISPR Therapeutics Provides Business Update and Reports Third ... - StreetInsider.com - November 9th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - StreetInsider.com - November 9th, 2023
- Sight Care Reviews - Overpriced or Worth the Hype? SightCare Pills ... - Journal of the San Juan Islands - November 9th, 2023
- 6 Amazing Health Benefits Of Giloy (Tinospora cordifolia) - WION - November 9th, 2023
- The Global Market for Bispecific Antibody Therapeutics Contract Manufacturing 2023-2030: Driven by Demand for Innovative Therapies and Promising... - November 7th, 2023
Recent Comments